H.C. Wainwright maintains $80 target on Beam Therapeutics stock
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc ...
Blue Trust Inc. Grows Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)
Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...
Nasdaq9d
Cantor Fitzgerald Upgrades Beam Therapeutics (BEAM)
Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. As of January 29, 2025, the average one-year ...
Positive Report for Beam Therapeutics (BEAM) from Bernstein
Beam Therapeutics (BEAM – Research Report) received a Buy rating and a $37.00 price target from Bernstein analyst William Pickering today. The ...
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...
Business Insider25d
Beam Therapeutics Positioned for Growth: Strong Pipeline and Financial Resilience Drive Buy Rating
Yanan Zhu, an analyst from Wells Fargo, reiterated the Buy rating on Beam Therapeutics (BEAM – Research Report). The associated price target remains the same with $75.00. Discover outperforming ...